<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83641">
  <stage>Registered</stage>
  <submitdate>24/02/2009</submitdate>
  <approvaldate>17/04/2009</approvaldate>
  <actrnumber>ACTRN12609000187246</actrnumber>
  <trial_identification>
    <studytitle>The Influence of Venous Tourniquet on Whole Blood Coagulation as Assessed by Thrombelastography (TEG)</studytitle>
    <scientifictitle>Measuring the effect of using a venous tourniquet for blood sampling on whole blood coagulation as assessed by thromboelastography in healthy volunteers</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Disorders of coagulation</healthcondition>
    <conditioncode>
      <conditioncode1>Blood</conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A single blood sample is taken from the antecubital fossa without the use of a venous tourniquet, using a 18g needle and 5 ml syringe. After a 5 minute period a second venous blood sample taken from the contralateral antecubital fossa. A venous tourniquet is use on this occasion for blood sampling. The tourniquet is applied for 30 seconds at 45mmHg prior venous puncture and released immediately after.This is also single venous puncture using a 18g needle and 5 ml syringe. This therefore forms a crossover study.</interventions>
    <comparator>Collection of blood sample without a venous tourniquet as explained above.</comparator>
    <control>Active</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Maximum clot strength as assessed by the thromboelastography (TEG) variable 'Maximum amplitude'</outcome>
      <timepoint>The Maximum amplitude (TEG value) time point is variable between patients and is not fixed.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Fibrinolysis, as assessed by thromboelastography and identified by the Lysis 30 and Lysis 60 variables.</outcome>
      <timepoint>The Lysis 30 and Lysis 60 (TEG values) time points are variable between patients and are not therefore fixed.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Initiation of clotting as assessed by thromboelastography and identified by the Reaction - time (R-time) variable.</outcome>
      <timepoint>The Reaction - time (R-time) time point is variable between patients and is not therefore fixed.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy volunteers</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. Prescription of any antiplatelet medication
2. Confirmed coagulation disorder (pathological or drug induced)
3. Confirmed systemic Inflammatory diseases
4. known pregnancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures>Pilot quality control study</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>24/02/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Perth Hospital</primarysponsorname>
    <primarysponsoraddress>Royal Perth Hospital
Wellington Street Campus
Perth 6000
WA</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Department of Anaesthesia</fundingname>
      <fundingaddress>Royal Perth Hospital
Wellington Street Campus
Perth 6000
WA</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Thromboelastography (TEG) is an in vitro method of measuring whole blood coagulation. It is, however, unknown whether the use of a venous tourniquet during blood sampling effects the results, making interpretation of a patients coagulation unreliable. This trial aims to answer this question.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Perth Ethics Committee</ethicname>
      <ethicaddress>Royal Perth Hospital
Wellington Street Campus
Perth 6000
WA</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Thomas Collyer</name>
      <address>Department of Anaesthesia
Royal Perth Hospital
Wellington Street Campus
Perth 6000
WA</address>
      <phone>+61 (0)424661181</phone>
      <fax />
      <email>tomcollyer@doctors.org.uk</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Thomas Collyer</name>
      <address>Department of Anaesthesia
Royal Perth Hospital
Wellington Street Campus
Perth 6000
WA</address>
      <phone>+61 (0)424661181</phone>
      <fax />
      <email>tomcollyer@doctors.org.uk</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Thomas Collyer</name>
      <address>Department of Anaesthesia
Royal Perth Hospital
Wellington Street Campus
Perth 6000
WA</address>
      <phone>+61 (0)424661181</phone>
      <fax />
      <email>tomcollyer@doctors.org.uk</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>